These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39222024)

  • 1. Impact of Microparticle Transarterial Chemoembolization (mTACE) on myeloid-derived suppressor cell subtypes in hepatocellular carcinoma: Clinical correlations and therapeutic implications.
    Yue Y; Ren Z; Wang Y; Liu Y; Yang X; Wang T; Bai Y; Zhou H; Chen Q; Li S; Zhang Y
    Immun Inflamm Dis; 2024 Sep; 12(9):e70007. PubMed ID: 39222024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
    Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
    Front Immunol; 2021; 12():624789. PubMed ID: 33717135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
    Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
    Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
    Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
    J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
    Wang D; An G; Xie S; Yao Y; Feng G
    Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma.
    Yue Y; Ren Z; Liu Y; Zhang Y
    J Interv Med; 2019 Feb; 2(1):21-26. PubMed ID: 34805865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
    Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
    J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study.
    Kamran AU; Liu Y; Li FE; Liu S; Wu JL; Zhang YW
    Medicine (Baltimore); 2015 Dec; 94(52):e2154. PubMed ID: 26717358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
    Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis.
    Hasan I; Gani RA; Lesmana LA; Kresno SB; Pandelaki J; Suwarto S
    Acta Med Indones; 2020 Oct; 52(4):326-333. PubMed ID: 33377877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
    Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
    J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization.
    Chen J; Chen YJ; Jiang N; Xu JL; Liang ZM; Bai MJ; Xing YF; Liu Z; Wu XY; Li X
    Oncologist; 2021 Aug; 26(8):e1434-e1444. PubMed ID: 33675070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience.
    Zhang Y; Huang G; Wang Y; Liang L; Peng B; Fan W; Yang J; Huang Y; Yao W; Li J
    Oncologist; 2016 Dec; 21(12):1442-1449. PubMed ID: 27486202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma.
    Park H; Jung JH; Jung MK; Shin EC; Ro SW; Park JH; Kim DY; Park JY; Han KH
    Hepatol Int; 2020 Mar; 14(2):249-258. PubMed ID: 32072464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
    Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
    AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
    [No Abstract]   [Full Text] [Related]  

  • 18. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
    Han K; Kim JH
    World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDSCs in liver cancer: A critical tumor-promoting player and a potential therapeutic target.
    Ma C; Zhang Q; Greten TF
    Cell Immunol; 2021 Mar; 361():104295. PubMed ID: 33508529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.